Osteopenia in children with cerebral palsy can be treated with oral alendronate

Abstract

Oral alendronate at a dose of 1 mg/kg/week for the treatment of osteopenia in children with cerebral palsy was found to be safe and effective.

Informing evidence‐based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update

“…The two reviewed mixed intervention studies are detailed in Table SIV (online supporting information). One study used oral alendronate in addition to calcium and vitamin D supplementation . The other study used oral risedronate with alfalcidol .…”

Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis

“…In the article by Henderson et al (14), to ensure uniformly adequate calcium and vitamin D intake, all participants were given supplements containing 1000 mg of calcium and 400 IU of vitamin D as the dose of calcium and vitamin recommended was considered required rather than therapeutic. In the article by Paksu et al (21), patients received 600 mg of calcium and 400 IU of vitamin D per day.…”

“…As reported previously, a strong correlation is observed between BMD and CP severity, as determined by the Gross Motor Function Classification System scale (4). Therefore, preventing or treating osteopenia in childhood is important to reach maximum bone mass and reduce the lifetime risk for osteoporosis (21,23). Bisphosphonates treatment in adults (25) and children (26) is effective for secondary osteoporosis induced by steroids.…”

“…In the article by Plotkin et al (20), pamidronate was given intravenously at a dosage of 0.75 mg/kg/day (maximum dose 45 mg/day) for 2 days every 16 weeks. In the article by Paksu et al (21), patients received 1 mg/kg/week of oral alendronate for a 1-year period.…”

Consensus guidelines on the use of bisphosphonate therapy in children and adolescents

“…BMD returned to baseline within 2 years 0.02, fracture reduced by 13% Henderson et al 18 21 3 Improvement in BMD z scores NA Paksu et al 22 26 Table 3 had two cohorts and therefore two outcomes as per References 17 and 23. BMD returned to baseline within 2 years 0.02, fracture reduced by 13% Henderson et al 18 21 3 Improvement in BMD z scores NA Paksu et al 22 26 Table 3 had two cohorts and therefore two outcomes as per References 17 and 23.…”